Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13. marts 2020 opdateret af: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Studieoversigt

Status

Ukendt

Betingelser

Detaljeret beskrivelse

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

50

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Clermont-Ferrand, Frankrig, 63000
        • CHU de Clermont-Ferrand

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år til 16 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Ingen indgriben: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
cardiac ectopic fat deposits
Tidsramme: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Tidsramme: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Tidsramme: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Tidsramme: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Tidsramme: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Tidsramme: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Tidsramme: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Tidsramme: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Tidsramme: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Tidsramme: Day 0
left myocardial regional function (MRI)
Day 0

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
macrovascularisation
Tidsramme: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Tidsramme: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Tidsramme: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Tidsramme: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Tidsramme: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Tidsramme: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Tidsramme: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Tidsramme: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Tidsramme: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Tidsramme: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Tidsramme: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Tidsramme: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Tidsramme: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Tidsramme: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Tidsramme: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Tidsramme: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Tidsramme: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Tidsramme: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Tidsramme: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Tidsramme: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Tidsramme: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Tidsramme: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Tidsramme: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Tidsramme: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Tidsramme: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Tidsramme: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Tidsramme: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Tidsramme: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Tidsramme: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Tidsramme: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Tidsramme: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Tidsramme: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Tidsramme: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Tidsramme: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Tidsramme: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Tidsramme: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Tidsramme: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Tidsramme: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Tidsramme: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Tidsramme: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Tidsramme: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Tidsramme: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Tidsramme: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Tidsramme: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Tidsramme: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Tidsramme: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Tidsramme: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Tidsramme: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Tidsramme: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Tidsramme: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Tidsramme: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Tidsramme: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Tidsramme: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Tidsramme: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Tidsramme: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Tidsramme: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Tidsramme: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Tidsramme: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Tidsramme: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Tidsramme: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Tidsramme: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Tidsramme: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Tidsramme: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Tidsramme: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Tidsramme: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Tidsramme: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Tidsramme: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Tidsramme: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Tidsramme: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Tidsramme: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Tidsramme: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Tidsramme: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Tidsramme: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Tidsramme: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Tidsramme: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Tidsramme: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Tidsramme: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Tidsramme: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Tidsramme: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Tidsramme: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Tidsramme: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Tidsramme: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Tidsramme: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Tidsramme: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Tidsramme: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Tidsramme: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Tidsramme: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Tidsramme: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Tidsramme: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Tidsramme: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Tidsramme: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Tidsramme: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Tidsramme: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Tidsramme: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Tidsramme: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Tidsramme: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Tidsramme: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Tidsramme: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Tidsramme: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Tidsramme: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Tidsramme: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Tidsramme: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Tidsramme: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Tidsramme: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Tidsramme: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Tidsramme: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Tidsramme: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Tidsramme: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Tidsramme: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Tidsramme: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Tidsramme: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Tidsramme: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Tidsramme: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Tidsramme: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Tidsramme: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Tidsramme: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Tidsramme: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Tidsramme: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Tidsramme: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Tidsramme: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Tidsramme: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Tidsramme: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Tidsramme: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Tidsramme: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Tidsramme: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Tidsramme: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Tidsramme: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Tidsramme: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Tidsramme: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Tidsramme: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Tidsramme: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Tidsramme: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Tidsramme: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Tidsramme: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Tidsramme: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Tidsramme: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Tidsramme: Day 0
measure of weight in kilograms
Day 0
weight
Tidsramme: Month 3
measure of weight in kilograms
Month 3
waist circumference
Tidsramme: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Tidsramme: Month 3
measure of waist circumference in centimetres
Month 3

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Forventet)

1. september 2020

Primær færdiggørelse (Forventet)

1. juni 2021

Studieafslutning (Forventet)

1. juni 2021

Datoer for studieregistrering

Først indsendt

10. februar 2020

Først indsendt, der opfyldte QC-kriterier

13. marts 2020

Først opslået (Faktiske)

17. marts 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. marts 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. marts 2020

Sidst verificeret

1. februar 2020

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Anden identifikator: ANSM)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Uafklaret

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med 3-month lifestyle intervention

Abonner